| Identification | Back Directory | [Name]
DEFOSLIMOD | [CAS]
171092-39-0 | [Synonyms]
DEFOSLIMOD
α-D-Glucopyranose, 2-deoxy-6-O-[2-deoxy-2-[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-2-[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-, 1-(dihydrogen phosphate) | [Molecular Formula]
C52H100N2O20P2 | [MDL Number]
MFCD09838377 | [MOL File]
171092-39-0.mol | [Molecular Weight]
1135.3 |
| Hazard Information | Back Directory | [Uses]
Defoslimod (OM 174) is an agonist for TLR4 receptor and acts as an immunomodulator. Defoslimod activates macrophages and dendritic cells, induces cytokines secretion, and exhibits antitumor efficacy in rats[1]. | [References]
[1] Isambert N, et al., Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172. DOI:10.1186/1471-2407-13-172 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|